Related references
Note: Only part of the references are listed.Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
Kazuaki Chayama et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016
Daniel J. Ruzicka et al.
BMC INFECTIOUS DISEASES (2018)
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
Juergen K. Rockstroh et al.
CLINICAL INFECTIOUS DISEASES (2018)
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
Namiki Izumi et al.
HEPATOLOGY INTERNATIONAL (2018)
EASL Recommendations on Treatment of Hepatitis C 2018
JOURNAL OF HEPATOLOGY (2018)
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti et al.
JOURNAL OF HEPATOLOGY (2018)
Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection
Yasuhiro Asahina et al.
LIVER INTERNATIONAL (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
Hiromitsu Kumada et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Treatment of hepatitis C with new fixed dose combinations
Vincent Soriano et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta-analysis
Zhipeng Liu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection: an integrated analysis
J. -F. Dufour et al.
JOURNAL OF HEPATOLOGY (2017)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
EASL Recommendations on Treatment of Hepatitis C 2016
JOURNAL OF HEPATOLOGY (2017)
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Edward Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
Teresa I. Ng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus
Fujie Xu et al.
CLINICAL INFECTIOUS DISEASES (2016)
Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir
Kerry Townsend et al.
AIDS (2016)
Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy
D. Banerjee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2
Yasuhiro Asahina et al.
HEPATOLOGY RESEARCH (2016)
Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures
Andrea Messori et al.
CLINICAL DRUG INVESTIGATION (2015)
Hepatitis C Infection in the Elderly
Sammy Saab et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan
Heather Bennett et al.
HEPATOLOGY INTERNATIONAL (2015)
Treatment of hepatitis C in difficult-to-treat patients
Peter Ferenci
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Hepatitis C and its impact on renal transplantation
Jose M. Morales et al.
NATURE REVIEWS NEPHROLOGY (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection
W. Alazawi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Treatment of chronic hepatitis C in Asia: When East meets West
Ming-Lung Yu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and FibroTest
Adays Vallet-Pichard et al.
HEPATOLOGY (2007)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling et al.
HEPATOLOGY (2006)
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
Y Iwasaki et al.
HEPATOLOGY (2006)
Share Paper
